These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31388632)

  • 1. Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals.
    Ioannou GN; Green PK; Berry K; Graf SA
    Hepatol Commun; 2019 Aug; 3(8):1124-1136. PubMed ID: 31388632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    Ioannou GN; Green PK; Berry K
    J Hepatol; 2017 Sep; ():. PubMed ID: 28887168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
    Tapper EB; Parikh ND; Green PK; Berry K; Waljee AK; Moon AM; Ioannou GN
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1197-1206.e7. PubMed ID: 31589975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
    Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
    J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
    Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
    World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
    Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
    Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding.
    Moon AM; Green PK; Rockey DC; Berry K; Ioannou GN
    Aliment Pharmacol Ther; 2020 Feb; 51(3):364-373. PubMed ID: 31773763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
    Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
    Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection.
    Krassenburg LAP; Zanjir WR; Georgie F; Stotland E; Janssen HLA; Hansen BE; Feld JJ
    Clin Infect Dis; 2021 Mar; 72(5):780-786. PubMed ID: 32052014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
    Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.
    El-Serag HB; Christie IC; Puenpatom A; Castillo D; Kanwal F; Kramer JR
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1442-1447. PubMed ID: 30932218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of
    Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
    Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
    J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
    Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
    Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable benefits of HCV eradication by direct acting antivirals and interferon-based therapy in patients with hepatocellular carcinoma undergoing surgical resection.
    Wu KC; Lee IC; Chi CT; Lei HJ; Chau GY; Yeh YC; Su CW; Huo TI; Chao Y; Lin HC; Hou MC; Huang YH
    Am J Cancer Res; 2021; 11(11):5526-5542. PubMed ID: 34873477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
    Daniel KE; Saeian K; Rizvi S
    J Viral Hepat; 2020 Feb; 27(2):195-204. PubMed ID: 31602715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
    J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.